2022-11-10
Camurus' Interim Report for third quarter 2022
Camurus' Interim Report for the third quarter, which was published today, showed that this was Camurus' financially best quarter to date.
Read the full press release on Camurus' website:
2022-11-10
Camurus' Interim Report for the third quarter, which was published today, showed that this was Camurus' financially best quarter to date.
Read the full press release on Camurus' website:
2019-08-26
Australia has announced that Camurus’ treatment Buvidal® (buprenorphine) will be listed through the Pharmaceutical B…
Read more2019-08-07
ISEC has launched three new products for better and safer surveillance of radioactive environments.
Read more2019-07-23
Camurus’ partner Braeburn have received a positive outcome in the US court proceedings which were initiated in April…
Read more2019-06-20
The FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-mon…
Read more2019-06-17
Starting June 2019, all Sandberg Development's office and production facilities will be cleaned and washed with DIRO…
Read more